Remdesivir for COVID-19: The NIAID Study Behind its Approval | GameChangers

Recently, Remdesivir was given Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) for use in COVID based on a heretofore unpublished study. The study, conducted by NIAID,  is the subject of this episode.

This episode is accredited for CPE.  For CE details and to claim credit click here:  https://bit.ly/3hn191p 

See omnystudio.com/policies/listener for privacy information.

Leave a Comment

Stay confident and competent.

Join over 100,000 Pharmacists & Technicians in our Pharmacy Community!

Experience the difference with CEimpact Education

Let's have a chat

0